Back to Journals » Cancer Management and Research » Volume 11

MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma

Authors Zhang W, Song B, Yang T

Received 7 October 2019

Accepted for publication 7 December 2019

Published 23 December 2019 Volume 2019:11 Pages 10675—10681

DOI https://doi.org/10.2147/CMAR.S233776

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Eileen O'Reilly


Wen-jing Zhang, Bing Song, Tao Yang

Department of General Surgery, Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China

Correspondence: Bing Song Email song2002bing@163.com

Introduction: The objective of this study was to assess the clinical significance of determining the levels of matrix metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and TIMP-2 in the peripheral blood of patients with differentiated thyroid carcinoma (DTC).
Methods: Forty-nine patients with benign thyroid lesions and 57 patients with DTC were examined using the enzyme-linked immunosorbent assay method preoperatively and 1 month after operation.
Results: The levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 in the peripheral blood of patients with DTC were significantly higher than those measured in patients with benign thyroid disease (P<0.05). After surgery, these levels in the peripheral blood of patients with benign thyroid lesions were not significantly changed (P>0.05). However, after operation, these levels in the peripheral blood of patients with DTC were significantly lower (P<0.05). These levels in the serum of patients with DTC which were tumor-node-metastasis stage, tumor diameter ≥l cm, infiltrating capsula outside or existing lymph metastasis were significantly higher than those reported in patients with early tumor-node-metastasis stage, tumor diameter <l cm or absence of lymph metastasis (P<0.05).
Discussion: Detecting the levels of these factors in peripheral blood is helpful in the diagnosis of benign and malignant thyroid lesions, and can be used as a basis for the prognosis of DTC.

Keywords: differentiated thyroid carcinoma, matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]